Sex-based differences in severity and mortality in COVID-19.

ALWANI, Mustafa <http://orcid.org/0000-0001-9463-3754>, YASSIN, Aksam <http://orcid.org/0000-0001-5457-3443>, AL-ZOUBI, Raed M. <http://orcid.org/0000-0002-0548-429X>, ABOUMARZOUK, Omar M., NETTLESSHIP, Joanne, KELLY, Daniel <http://orcid.org/0000-0002-7463-0692>, AL-QUDIMAT, Ahmad R. and SHABSIGH, Ridwan

Available from Sheffield Hallam University Research Archive (SHURA) at:

http://shura.shu.ac.uk/28405/

This document is the author deposited version. You are advised to consult the publisher's version if you wish to cite from it.

Published version

ALWANI, Mustafa, YASSIN, Aksam, AL-ZOUBI, Raed M., ABOUMARZOUK, Omar M., NETTLESSHIP, Joanne, KELLY, Daniel, AL-QUDIMAT, Ahmad R. and SHABSIGH, Ridwan (2021). Sex-based differences in severity and mortality in COVID-19. Rev Med Virol.

Copyright and re-use policy

See <http://shura.shu.ac.uk/information.html>
Sex-based differences in severity and mortality in COVID-19

Mustafa Alwani¹² | Aksam Yassin¹³⁴ | Raed M. Al-Zoubi¹⁵ | Omar M. Aboumarzouk⁶⁷⁸ | Joanne Nettleship⁹ | Daniel Kelly⁹¹⁰ | Ahmad R. AL-Qudimat¹ | Ridwan Shabsigh¹¹

¹Surgical Research Section, Hamad Medical Corporation, Doha, Qatar
²Jordan University of Science and Technology, School of Medicine, Irbid, Jordan
³Department of Surgery, Hamad Medical Corporation, Division of Urology/Andrology & Men’s Health, Doha, Qatar
⁴Center of Medicine and Health Sciences, Dresden International University, Dresden, Germany
⁵Department of Chemistry, Jordan University of Science and Technology, Irbid, Jordan
⁶Department of Surgery, Hamad Medical Corporation, Doha, Qatar
⁷College of Medicine, Qatar University, Doha, Qatar
⁸College of Medicine, University of Glasgow, Glasgow, UK
⁹Department of Oncology and Metabolism, Medical School, University of Sheffield, Sheffield, UK
¹⁰Biomolecular Research Centre, Sheffield Hallam University, Sheffield, UK
¹¹Department of Urology, Columbia University College of Physicians and Surgeons, New York, New York, USA

Correspondence
Aksam A Yassin, Rathausallee 94 a, 22846 Norderstedt-Hamburg, Germany.
Email: yassin@t-online.de

Funding information
Open access funding enabled and organized by Projekt DEAL.

Summary
The current coronavirus disease (COVID-19) pandemic caused by novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has a male bias in severity and mortality. This is consistent with previous coronavirus pandemics such as SARS-CoV and MERS-CoV, and viral infections in general. Here, we discuss the sex-disaggregated epidemiological data for COVID-19 and highlight underlying differences that may explain the sexual dimorphism to help inform risk stratification strategies and therapeutic options.

KEYWORDS
COVID-19, dimorphism, sex

Abbreviations: ACE2, Angiotensin converting enzyme-2; ARDS, acute respiratory distress syndrome; ARDS, acute respiratory distress syndrome; Autoimmune respiratory distress syndrome; Cav1, Caveolin 1; CD, Cluster of Differentiation; CDC, Centers for Disease Control and Prevention; CFR, case fatality ratio; COCP, combined oral contraceptive pill; COPD, Chronic obstructive pulmonary disease; CXCR3, Chemokine receptor; DCs, Dendritic Cell; DDX3Y, DEAD-Box Helicase 3 Y-Linked; GWAS, Gene-wide association study; ICU, Intensive care unit; IFN α, Interferon α; IFN β, Interferon β; IFN, Interferon; IL, Interleukin; IL-1β, Interleukin1β; IL4, Interleukin4; IL6, Interleukin6; IL7R, Interleukin-7 receptor; IL8, Interleukin8; NF-κB, Nuclear factor kappa B; PAMPs, Pathogen-associate molecular patterns; pDCs, Plasmacytoid dendritic cell; SARS-CoV, severe acute respiratory syndrome coronavirus 2; T2DM, Type 2 Diabetes Mellitus; Th2, T follicular helper; Th1, T helper type 1; Th2, T helper type 2; TLR, Toll-like receptors; TLR7, Toll-like receptors7; Tmprss2, Transmembrane protease serine 2; vWF, von Willebrand factor.

Please address reprints requests to Prof. Aksam A. Yassin

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2021 The Authors. Reviews in Medical Virology published by John Wiley & Sons Ltd.

Rev Med Virol. 2021;1–11.
The current coronavirus disease (COVID-19) pandemic, caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has overwhelmed healthcare systems around the world bringing significant morbidity and mortality. The World Health Organization has declared it to be a public health emergency of international concern. As of 31 October 2020, there have been >45 million confirmed cases reported worldwide, with deaths exceeding 1.18 million and still rising.\(^{3}\) Whilst most reported cases of COVID-19 experience mild to moderate symptoms including fever, persistent cough, loss of taste and smell, or dyspnoea, about 15% of infected adults develop severe pneumonia requiring oxygen supplementation via invasive mechanical ventilators. Among these, 5% progress to a critical stage with acute respiratory distress syndrome (ARDS), hypoxic respiratory failure and multi-organ failure, that necessitates mechanical ventilation.\(^{2,3}\)

Epidemiological data from previous coronavirus epidemics-SARS-CoV (2002) and Middle Eastern respiratory syndrome coronavirus (MERS, 2012) highlighted differences in their manifestation based on sex, with men being consistently more severely affected than women.\(^{5–7}\) Early reports of COVID-19 also suggest a sex imbalance, with men at a higher risk of more severe disease and increased case fatality ratio (CFR).\(^{3,8}\) Publicly available sex-disaggregated data from several governments compiled by the Global Health 50/50 research initiative also show, despite similar numbers of COVID-19 cases in men and women, an increased fatality rate in men as outlined in Figure 1, with the male:female ratio of deaths among confirmed cases ranging from 1.0 in Pakistan and Canada to 2.1 in Wales.\(^{9}\) In addition to fatality, hospitalizations and admissions to intensive care units (ICU) can serve as a measure of disease severity. A review of epidemiological data by Gebhard et al. (2020) comprising confirmed COVID-19 cases in several countries including China, Italy and Spain show that there were 50% more men requiring hospitalization compared to women, with ICU admission being three to fourfold higher.\(^{10,11}\) A meta-analysis of 15 independent studies that recorded sex disaggregated patient outcomes found men had an odds ratio of 1.31 to develop a severe COVID-19 infection compared to women.\(^{12}\) United States of America has the highest number of COVID-19 cases to date and early reports by the Centers for Disease Control and Prevention (CDC) across 14 states also observed higher hospitalization rates for men.\(^{13}\) A recent count by Global Health 50/50 also confirms this indication of sex imbalance in disease severity across several countries (Figure 2).\(^{7}\) There are, however, some limitations to this data set particularly as the interaction between age and sex remains unexplored.

On investigating the magnitude of differences in survival for both sexes in Europe across different age groups, Ahrenfeldt et al. (2020) reported that the relative risk of dying from COVID-19 is consistently elevated in men across all age groups with the differences increasing until the age range 60–69 years.\(^{14}\) Thereafter, the sex difference in survival decreases and was at its lowest for ages 80+.\(^{14}\) A study comprising of 227,000 confirmed cases of COVID-19 pooled from Italy, Germany, Spain and Switzerland also suggested that the sex difference in fatality is most pronounced in the ages 50–59, and decreases subsequently with increasing age.\(^{10}\) Interestingly, as per the Global Health 50/50 data, numbers of confirmed cases are similar for men and women, suggesting equal infection rates.\(^{6}\) More detailed reports on incidence rates from Switzerland and Germany also suggest similar proportions of COVID-19 cases in men and women at all age groups (Figure 3), thereby highlighting the worsened prognosis in infected males compared to females.\(^{15,16}\)

To some extent, sex difference in COVID-19 expands to affect the male reproductive system either directly or indirectly as some articles suggest.\(^{17}\)

As vaccines and other treatment modalities are researched and developed in attempt to contain the recurrent surges in infections for this pandemic, better understanding of the sex imbalance and its underlying biology can help inform public health strategies for testing and intervention by stratifying groups at high risk for severe disease; and help improve therapeutic options by allowing gender-specific targeted treatments. Herein, we discuss several factors that may contribute to the sex differences observed in COVID-19 patients, including possible biological reasons, contributions of comorbidities, and highlight any role that gender may play.

## 2 | SEX DIFFERENCES IN VIRAL ENTRY

Angiotensin converting enzyme-2 (ACE2) catalyses the conversion of angiotensin-II to angiotensin (1–7), and plays a vital role in homeostasis of blood pressure, inflammatory responses and blood coagulation.\(^{18}\) ACE2 is expressed in a range of tissues including nasal and respiratory epithelial cells, blood vessels and kidneys.\(^{19–22}\) As with SARS-CoV, membrane-bound ACE2 serves as a receptor for the SARS-CoV-2 spike (S) glycoprotein, facilitating its attachment to the cell surface and subsequent entry.\(^{23}\)

The expression levels of ACE2 correlate with the risk of COVID-19 severity, with children who have lower ACE2 expression in their nasal epithelium having a lower risk compared to adults.\(^{24}\) However, evidence regarding a sex disparity in ACE2 expression is unclear. A phenomenon, termed X chromosome inactivation, is an epigenetic process that silences one of the two X-chromosomes in females to maintain balance in gene expression dosage.\(^{25}\) The ACE2 gene is located on the X chromosome, and is thought to have higher levels of expression in females. This is because it has been reported that ACE2, frequently ‘escapes’ inactivation that occurs to balance expression dosage between the sexes, has an uncharacteristic heterogeneous pattern of male-female expression based on the tissues.\(^{26}\) In pre-clinical studies, ACE2 expression has been reported to be higher in female rat lungs and kidneys.\(^{24,27}\) Conversely, oestrogen downregulates the expression of ACE2 in vitro and in gonadectomised female mice.\(^{28,29}\) In human tissues, studies have suggested no significant difference in the expression of ACE2 for both sexes in respiratory tissues,\(^{30–32}\) and in circulation are more elevated for male patients with comorbidities such as cardiovascular diseases.\(^{33}\)
| Country         | Confirmed Cases | Confirmed Deaths | Proportion of deaths in confirmed cases | Male:female ratio |
|----------------|-----------------|------------------|----------------------------------------|-------------------|
|                | Number Male (%) | Number Male (%)  | Total (%) Male (%)                      |                   |
| USA            | 5,706,415       | 190,804          | 3.5                                    | 3.3               |
| India          | 2,877,791       | 3,711            | 0.1                                    | 0.2               |
| Argentina      | 928,391         | 8,597            | 0.9                                    | 2.2               |
| Colombia       | 919,083         | 27,985           | 3                                       | 3.9               |
| Peru           | 853,974         | 33,347           | 3.9                                    | 5.2               |
| Spain          | 831,180         | 20,518           | 2.5                                    | 10.9              |
| Mexico         | 829,396         | 84,098           | 10.2                                   | 12.6              |
| South Africa   | 667,475         | 14,896           | 2.2                                    | 2.1               |
| Chile          | 511,782         | 294              | 0.1                                    | 1.3               |
| England        | 447,666         | 42,347           | 9.5                                    | 11.9              |
| Bangladesh     | 379,730         | 5,555            | 1.5                                    | 1.6               |
| Indonesia      | 349,160         | 12,268           | 3.5                                    | 4.1               |
| Philippines    | 344,713         | 6,372            | 1.8                                    | 2.0               |
| Germany        | 328,118         | 9,542            | 2.9                                    | 3.7               |
| Italy          | 327,357         | 36,051           | 11                                     | 13.2              |
| Turkey         | 325,445         | 8,441            | 2.6                                    | 3.2               |
| Brazil         | 292,736         | 1,845            | 0.6                                    | 0.7               |
| Pakistan       | 289,832         | 6,190            | 2.1                                    | 2.1               |
| Ukraine        | 270,587         | 5,122            | 1.9                                    | 2.5               |
| Netherlands    | 188,785         | 6,631            | 3.5                                    | 4.3               |
| Canada         | 167,731         | 9,495            | 5.7                                    | 5.6               |
| Belgium        | 165,113         | 10,186           | 6.2                                    | 6.6               |
| Romania        | 157,362         | 5,467            | 3.5                                    | 4.5               |
| Ecuador        | 148,171         | 11,873           | 8                                       | 10.1              |
| Czech Republic | 118,024         | 759              | 0.6                                    | 1.4               |
| Nepal          | 111,802         | 562              | 0.5                                    | 0.4               |
| Sweden         | 100,654         | 5,089            | 5.9                                    | 7.3               |
| Guatemala      | 95,732          | 3,290            | 3.4                                    | 4.2               |
| Dominican Rep. | 93,732          | 1,710            | 1.8                                    | 2.4               |
| Portugal       | 91,193          | 2,117            | 2.3                                    | 2.6               |
| Costa Rica     | 89,223          | 1,108            | 1.2                                    | 1.5               |
| Panama         | 79,402          | 373              | 0.5                                    | 2.8               |
| Switzerland    | 65,047          | 11,873           | 8                                       | 10.1              |
| Moldova        | 63,475          | 1,478            | 2.3                                    | 2.9               |
| Austria        | 57,762          | 879              | 1.5                                    | 1.7               |
| China          | 55,924          | 2,114            | 3.3                                    | 4.7               |
| Paraguay       | 49,075          | 1,077            | 2.2                                    | 2.6               |
| Republic of Ireland | 42,483 | 1,827 | 4.3 | 4 | 4 | 1.17 |
| Scotland       | 39,926          | 4,301            | 2.1                                    | 2.4               |
| Afghanistan    | 39,093          | 1,378            | 3.5                                    | 3.8               |
| Kenya          | 36,301          | 634              | 1.7                                    | 2.3               |
| Denmark        | 33,101          | 674              | 2                                       | 2.4               |
| Wales          | 31,197          | 1,670            | 5.4                                    | 7.1               |
| Australia      | 27,301          | 896              | 3.3                                    | 3.3               |
| South Korea    | 26,095          | 434              | 1.7                                    | 2.3               |
| Northern Ireland | 21,888 | 597 | 2.7 | 3.1 | 2.4 | 1.3 |
| Greece         | 21,310          | 456              | 2.1                                    | 2.4               |
| North Macedonia | 18,800 | 760 | 4 | 5 | 3.1 | 1.63 |
| Morocco        | 17,015          | 1,895            | 10.9                                   | 3                 |
| Albania        | 15,752          | 429              | 2.7                                    | 3.8               |
| Norway         | 15,639          | 277              | 1.8                                    | 1.8               |
| Iran           | 14,991          | 853              | 5.7                                    | 5.9               |
| Bosnia and Herzegovina | 12,710 | 354 | 2.8 | 3.5 | 2 | 1.78 |
| Kyrgyzstan     | 12,498          | 155              | 1.2                                    | 1.6               |
| Maldives       | 10,874          | 32               | 0.3                                    | 0.2               |

**Figure 1** Sex-disaggregated data of confirmed COVID-19 cases and deaths from countries with >10,000 cases. Cases and deaths are only reported where sex-disaggregated data is available, and not total cases. Data from Global Health 50/50 COVID-19 data tracker as of 31st October 2020.⁹
**FIGURE 2** Disease severity is higher in males as measured by hospitalizations and ICU admissions. Graphs reproduced from Global Health 50/50 COVID-19 data tracker.  

**FIGURE 3** Reported COVID-19 cases in Germany by age group and gender ($n = 254,549$) (Data accessed on 10/09/2020, from https://www.rki.de/EN/Content/infections/epidemiology/outbreaks/COVID-19/Situationsberichte_Tab.html)
together, the levels of ACE2 expression varies based on tissues and underlying comorbidities and therefore it may not be a strong predictor for disease severity isolation.

Transmembrane protease serine 2 (TMPRSS2) is also vital for viral entry, following its binding to ACE2, by priming the viral S protein (by proteolytic cleavage) and mediating fusion of viral and cell membranes. Indeed, in an in vitro model, inhibiting TMPRSS2 activity partially inhibited the entry of SARS-CoV-2 into lung epithelial cells. In vivo, TMPRSS2 deficient mice demonstrated reduced weight loss and inflammatory response in the lungs following SARS-CoV and MERS-CoV infections, suggesting decreased severity.

Interestingly, a study by Asselta et al. (2020), which compared the expression of TMPRSS2 in the two sexes from a large Italian cohort observed a higher expression of TMPRSS2 in bronchial epithelial cells in the males compared to females. TMPRSS2 plays a pivotal role in the development and progression of prostate cancer via gene fusion, and is strongly upregulated in response to androgens. These data suggests that TMPRSS2 expression might mediate the sex disparity observed in severity of COVID-19. However, it is unclear if androgen signalling can modulate TMPRSS2 expression in respiratory tissues, and whether low level of androgens present in women can maintain TMPRSS2 expression in respiratory tissues. Further research is therefore required to determine if there is a sex-biased expression and/or regulation of ACE2 and TMPRSS2 that confers increased severity COVID-19 in males compared to females. This is especially topical with current treatment strategies targeting these proteins.

3 | SEX DIFFERENCES IN IMMUNE RESPONSES

Sex-based differences in immune responses have been reported for adults and children, suggesting an influence of both the sex chromosome and hormones on the immune system. The X chromosome encodes several genes that regulate immune function and is fundamental in shaping sex-specific immune responses. As mentioned previously, X chromosome inactivation silences one of the two X-chromosomes in females to maintain balance in gene expression dosage. This process leads to 50% cells in females having the maternal X chromosome inactivated, whilst the paternal X chromosome is inactivated in the rest, a phenomenon termed as ‘cell mosaicism’. This provides females with a greater plasticity and adaptability in response to infections, especially in case of X-linked mutations by expressing the corresponding wild-type allele on the other X chromosome. Furthermore, some immune related genes are partially reactivated in female lymphocytes to confer enhanced immunity to infectious diseases.

3.1 | Role of innate immunity

The sexual dimorphism in immune responses to vaccines and viral infections has been well documented. There is compelling evidence showing that females differ in their innate recognition and response to viral infections, and mount a greater inflammatory and humoral immune response. As a result, both the prevalence and intensity of viral infections are often lower for females. Toll-like receptor are a class of innate immune pattern recognition receptors that recognize bacterial or viral pathogen-associated molecular patterns. TLR7 is an endosomal receptor expressed constitutively in plasmacytoid dendritic cells (pDCs) and B-cells, and is capable of detecting single-stranded ribonucleic acids from viruses, including coronavirus. Upon recognition of viral infection, TLR7 triggers an antiviral type I interferon (IFN) response which serves to control viral replication and activate an adaptive immune response to clear the infection.

TLR7 is encoded on the X-chromosome, and is one of the 23% of the X-linked genes that exhibit incomplete inactivation resulting in increased dosage in females. Using single-cell analyses, Souris et al. (2018) demonstrated that TLR7 is transcribed on both X chromosomes in pDCs and B-cells, and correlates with higher TLR7 protein expression in female leucocyte populations. This disparity in TLR7 expression enhances innate immune responses to viruses, and may confer females an advantage as observed with COVID-19. Indeed, some early COVID-19 case-reports suggest a link between loss-of-function TLR7 mutations and increased disease severity in young patients.

Interferon α and β (IFNα and IFNβ) are the primary effector cytokines of the type I IFN response downstream of TLR activation, and critical players of the immune system, linking innate to adaptive immunity. IFNα/β production by pDCs is primarily mediated through the stimulation of TLR7 during viral infection, and is essential for the maturation of DCs to effective antigen-presenting cells with increased ability to activate T cells. Several studies have shown that pDCs from females produce more IFNα/β than males, following TLR7 activation by viral RNA. In a study cohort of 50 COVID-19 patients with mild/moderate to critical severity, Hadjadj et al. (2020) employed an integral approach by conducting in-depth phenotypical analysis of immune cells, whole-blood transcriptomics and cytokine measurements. They observed that the severity of the disease characterized by persistent viral load in the blood and exacerbated inflammation associated with highly impaired type I IFN response, with very low levels of IFNα and no IFNβ. Taken together, this suggests that females may have a better prognosis following SARS-CoV-2 infection partly because of their heightened type I IFN response, and enhancing type I IFN response could serve as a therapeutic possibility for COVID-19.

Genetically, a British gene-wide association study attained in critically ill COVID-19 patients, revealed loss-of-function mutation in the one of the responsible genes for IFNα and IFNβ expression called IFNAR2, explaining the lower interferons level in the critically ill patients specifically.

Whilst the initial immune response against the pathogen is vital to protect the host, an overactivation of the response that results overproduction in pro-inflammatory cytokines causes immunopathology leading to multiple organ failure and ultimately death. In a
recent study, Liu et al. (2020) evaluated the severest multi-organ dysfunctions during entire hospitalization between males and females which helps predict in-hospital death. They observed that whilst multiple key factors that characterize a ‘cytokine storm’ were elevated (pro-inflammatory cytokines such as TNFa, IL6 and IL8) in females during the acute infection phase, these mediators were lower when measured over the whole duration of hospitalization, possibly offering a survival advantage. However, when the infection persisted, the heightened immune response in females led to more ferocious organ injuries and their survival advantage diminished.

3.2 Role of adaptive immunity

In general, females mount a much stronger cellular and humoral immune response post viral infections and vaccinations. T cells play an integral role in cell mediated immune response, with CD4+ T cells orchestrating the B cell response for antibody production and CD8+ T cells responsible for the killing of infected cells and reducing viral burden. Akin to SARS-CoV, several reports following SARS-CoV-2 infection describe a correlation of COVID-19 severity with lymphopenia, and drastically reduced circulating CD4+ and CD8+ T cells. In a longitudinal study comparing immune responses between sexes, Takahashi et al. (2020) observed that whilst T cell lymphopenia occurred in both sexes, female patients mounted a more robust T cell activation, particularly for CD8+ T cells. A balance between the CD4+ pro-inflammatory T helper type 1 (Th1) and anti-inflammatory type 2 (Th2) subtypes is vital for regulating the immune response and resolving of the infection without damaging host tissue. Studies with SARS-CoV and MERS-CoV describe upregulation of Th1 cytokines, dysregulating the Th1/Th2 balance. Sexual dimorphism in Th1 and Th2 responses based on the stages of infection have been reported previously, and further research is needed to elucidate if it plays a role in COVID-19.

T follicular helper (Tfh) cells, are a subset of CD4+ T cells, responsible for the differentiation of B cells into plasma cells and memory B cells. In patients with severe disease particularly, the improved outcomes for females can also be attributed to higher levels of circulating IgG antibodies against SARS-CoV-2 as observed by Zeng et al. (2020). Furthermore, in a comprehensive analysis of sex differences in B-cell gene expression, Fan et al. (2014) found over 350 differentially expressed genes between males and females. These include upregulation of immune response genes such as Cav1, CXCR3, and downregulation of inflammatory genes such as IL7R and DDX3Y, and may account for some of the observed sex bias observed in COVID-19. Taken together, the reports suggest that the immune landscape in COVID-19 is considerably different between the two sexes and may contribute to the higher susceptibility observed in males. These, along with genes such as ACE2 and TLR7 that escape inactivation, cause a gene dosage imbalance between the sexes and may contribute to the immune disparity.

3.3 Role of sex hormones

The role of sex hormones in regulating immunity is well characterized, and is likely to play a role in differences in the severity of COVID-19 between males and females. Oestrogen has a dual effect based on its levels. At low doses similar to those in post-menopausal women, oestrogen is immuno-stimulatory and induces differentiation of inflammatory dendritic cells, higher production of IL-4 and IFNα, and an increased Th1 type and cell mediated responses. Conversely, at higher doses observed in premenopausal women, oestrogen promotes anti-inflammatory Th2 responses and is inhibitory to the pro-inflammatory innate immune response. Indeed, Channappanavar et al. (2017) demonstrated that mortality in female mice infected with SARS-CoV increased following ovariectomy or exposure to oestrogen receptor antagonist suggesting a protective role of oestrogen receptor signalling. A similar protective effect of oestrogen has also been suggested in a recent pre-print study which investigated the association of oestrogen with severity of COVID-19 symptoms. The study observed a higher risk in post-menopausal women; and in younger women who did not take the combined oral contraceptive pill (COCP) compared to those of similar aged women taking COCP. A similar observation was reported by Ding et al. (2020), who showed that post-menopausal women were at a greater risk of hospitalization, and that oestrogen levels had a protective effect against disease severity. This protective effect of oestrogen was attributed to reduced levels of inflammatory IL-6, IL-8 and TNFα.

Early reports from China, Germany and Italy have suggested that low testosterone levels strongly correlate with disease severity and the need for intensive care in male patients. Testosterone immunosuppresses by reducing the production of pro-inflammatory IL-6, IL-1β and TNFα via inhibition of the NF-kB pathway. In fact, IL-6 is a key mediator of disease progression to ARDS in COVID-19, and a clinical trial of tocilizumab, an IL-6 receptor blocker, is approved in China for patients with severe disease. This suggests that the role of testosterone on the immune response to SARS-CoV-2 may be beneficial to patient outcomes potentially suppressing uncontrolled inflammatory responses. Conversely, men with higher levels of testosterone have weakened immunity and produce the lowest antibody responses to annual flu vaccinations.

Low serum testosterone can increase the expression of ACE-2 receptors and TMPRSS2, with patients reportedly developing severe manifestations of COVID-19 infections which require assisted ventilation as a result of the upregulation of ACE-2 receptors in lower respiratory cells increasing risk of lung damage and respiratory muscle catabolism. Reduced testosterone in men can also inhibit pulmonary endothelial cell function as SARS-CoV-2 reduces ACE-2 concentrations by binding and increasing angiotensin-II while lowering angiotensin 1-7. As a result of this process superoxide species become increased, leading to oxidative stress induced endothelial cell dysfunction and localised inflammation. Consequently, von Willebrand factor expression can increase and
development of thrombosis in the alveolar capillaries, a precursor of ARDS, ensues.97–99

Testosterone levels are known to decline following onset of disease, and in particular, during infections with low testosterone often considered a marker of ill health.100 This may have evolutionary origins to move energy away from high-energy consuming anabolic processes to allow instead most energy for strengthening the immune response. It has been suggested that COVID-19 might deteriorate serum testosterone level in SARS-CoV-2 infected male patients and that a lower pre-infection testosterone may significantly increase the risk of ICU transfer and mortality.101 The authors additionally propose possible improvement in clinical outcomes with the testosterone treatment in SARS-CoV-2 infected hypogonadal male patients. However, due to the varying effects on different aspects of the immune system (it is not likely that testosterone’s anti-inflamatory effects would reduce all parts of immune function equally) it would be necessary to look at testosterone effects on various functions of both innate and adaptive immunity in a variety of contexts to elucidate its therapeutic potential, as well as testosterone deficiency in hypogonadism contribute to increase the risk of comorbidities such as type 2 diabetes mellitus (T2DM), and cardiovascular diseases.101–103 Thus, increase the rate of ICU admissions and mortality in COVID-19 patients as Cayan S et al. suggests.101

Furthermore, a systemic review spotlights in the acute management of COVID-19, T2DM and hypogonadism suggests that treating testosterone deficient COVID-19 patients with testosterone might be considered in the future as Testosterone reduces the risk of T2DM, and boosts the body inflammatory response against the virus acutely.102 However, further studies required in order to reveal the optimal effect of Testosterone replacement therapy.

4 | SEX AND GENDER RELATED RISK FACTORS

Clinical data has highlighted that specific comorbidities increase the risk of COVID-19 severity. Guan et al. (2020) showed that COVID-19 patients with comorbidities have a poorer prognosis, and that greater number of comorbidities correlate to poorer clinical outcomes.7 Specific comorbidities associated with poorer patient outcomes included chronic obstructive pulmonary disease (COPD), Obesity, diabetes, cerebrovascular disease, cancer and hypertension.2,102–104 Globally, men have more of these morbidities than women,105 placing them at a higher risk for severe disease.

In addition to biological sex-based differences, gender as defined as the social and cultural norms, roles, attributes and behaviours that society considers appropriate for males and females, is likely to play a role in the incidence and fatality of COVID-19. A meta-analysis by Zhao et al. (2020) which analysed data from 1726 patients showed that smoking has a significant association with COVID-19 severity, with odds ratio of 2.0 (95%CI 1.3–3.1).106 This observation has since been confirmed by several studies that also reported increased disease severity and death in COVID-19 patients who smoke, potentially related to higher expression of ACE2.107,108 Indeed, gender differences in smoking rate between men and women has been suggested to contribute to their predisposition to COVID-19 progression.109 However, a male bias is often still observed in countries reporting equal rates of current smokers between the genders, and large variations across age and ethnicity confound this relationship resulting in review of the current literature not supporting smoking as a predisposing factor in men for COVID-19 incidence or severity.109 Other gender-based differences include delay in accessing health services by men that lead to higher fatality, as suggested from the data of the Ebola outbreak.110 Furthermore, handwashing behaviour, which is the primary public health message in this pandemic, also exhibits a sex difference with women being more frequent adherers to guidelines.111 Therefore, understanding the sex differences in COVID-19 severity and mortality requires recognition of both the biological and the social factors that may play a role.

4.1 | Sex disparity in ‘long–COVID’

It is becoming evident that the impact of the SARS-CoV-2 pandemic is likely to be much larger due to the long-term persistence of symptoms in patients following the initial acute stage. In a subset of COVID-19 patients, a syndromic state post the acute symptomatic phase has been reported which includes a wide range of symptoms such as dyspnoea, extreme fatigue, tachycardia and mental fog.112–114 This prolonged symptomatic phase (beyond 3-weeks) is being referred to as ‘Long-COVID’, ‘Long-haulers’ or ‘Chronic COVID Syndrome’, and is still poorly understood.

A recent report describing data collected from over 4000 patients using a mobile application showed that symptoms persist for 28 days in 13% patients, of which 4.5% and 2.3% experienced symptoms for 56 and 94 days respectively.115 The study also reported that age significantly associated with long-COVID, rising from 10% in 18–49 year olds, to 22% in those above 70. Interestingly, and conversely to the acute phase, long-COVID seems to affect women disproportionately (14.9%) compared to men (9.5%), with females aged 50–60 having the highest odds ratio, although this sex effect was not significant in the older age-group (>70).115 Whilst the aetiology of the syndrome and reasons for any sex disparity needs further research, a pre-existing asthma condition, which is more common in women, increased the odds of having long-COVID.115,116

5 | CONCLUSION

The sex disparities in COVID-19 severity and mortality are multifactorial, may also be resulted from the sex-difference comorbidities and behaviours, thus underline the need to collect sex and age-disaggregated data to better understand disease pathology and guide clinical care. It has also highlights the need to incorporate sex and gender analyses in any therapeutic strategies under consideration, and vaccine development protocols. Furthermore, the consistencies with previous coronavirus pandemics suggest that the public health
policies and risk stratification should take sex into consideration for any future outbreaks.

ACKNOWLEDGEMENTS
The publication of this article was funded by Dresden International UNIVERSITAET GMBH and the Qatar National Library. Editorial support for this manuscript was provided by Astra-Health, www.astra-health.co.uk.

Open Access funding enabled and organized by Projekt DEAL.

AUTHORS CONTRIBUTIONS
Ridwan Shabsigh: Supervision, Concept, Literature Search, Manuscript Writing, Manuscript Grammatically Revision, Critical Revision.
Aksam Yassin: Supervision, Concept, Manuscript Writing, Manuscript Grammatically Revision, Critical Revision.
Mustafa Alwani: Concept, Literature Search, Manuscript Writing, Manuscript Grammatically Revision, Final Revision (Editor and Reviewer Comments).
Joanne Nettleship: Literature Search, Daniel Kelly: Literature Search, Manuscript Grammatically Revision, Final Revision (Editor and Reviewer Comments).
Ahmad R. Al-Qudimat: Final Revision (Editor and Reviewer Comments).

DATA AVAILABILITY STATEMENT
The data that support the findings of this study are openly available in [Global Health 50/50] at [globalhealth5050.org], reference number.9

ORCID
Mustafa Alwani https://orcid.org/0000-0001-9463-3754
Aksam Yassin https://orcid.org/0000-0001-5457-3443
Raed M. Al-Zoubi https://orcid.org/0000-0002-0548-429X

REFERENCES
1. World Health Organization. WHO Coronavirus Disease Dashboard. https://covid19.who.int/. Accessed September 7, 2020.
2. Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708-1720.
3. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507-513.
4. Karlberg J, Chong DS, Lai WY. Do men have a higher case fatality rate of severe acute respiratory syndrome than women do? Am J Epidemiol. Feb 1. 2004;159(3):229-231.
5. Alghamdi IG, Hussaini AI, Almalki SS, Alghamdi MS, Alghamdi MM, El-Sheemy MA. The pattern of Middle East respiratory syndrome coronavirus in Saudi Arabia: a descriptive epidemiological analysis of data from the Saudi Ministry of Health. Int J Gen Med. 2014;7:417-423.
6. Jansen A, Chiew M, Konings F, Lee CK, Allan L. On behalf of the world Health Organization Regional Office for the Western Pacific MEMENT. Sex matters - a preliminary analysis of Middle East respiratory syndrome in the Republic of Korea. Western Pac Surveill Response J. 2015;6(3):68-71.
7. Chen X, Chuhtai AA, Dyda A, MacIntyre CR. Comparative epidemiology of Middle East respiratory syndrome coronavirus (MERS-CoV) in Saudi Arabia and South Korea. Emerg Microb Infect. 2017;6(6):e51.
8. Zhao S, Cao P, Chong MKC, et al. COVID-19 and gender-specific difference: analysis of public surveillance data in Hong Kong and Shenzhen, China, from January 10 to February 15, 2020. Infect Control Hosp Epidemiol. 2020;41(6):750-751.
9. Global Health 50/50. The COVID-19 Sex-Disaggregated Data Tracker. https://globalhealth5050.org/the-sex-gender-and-covid-19-project/. Accessed September 7, 2020.
10. Gebhard C, Regitz-Zagrosek V, Neuhauser HK, Morgan R, Klein SL. Impact of sex and gender on COVID-19 outcomes in Europe. Biol Sex Differ. 2020;11(1):29.
11. Grasselli G, Zangrillo A, Zanella A, et al. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy Region, Italy. JAMA. 2020;323(16):1574-1581.
12. Ueyama H, Kuno T, Takagi H, et al. Gender difference is associated with severity of coronavirus disease 2019 infection: an insight from a meta-analysis. Crit Care Explor. 2020;2(6):e0148.
13. Centers for Disease Control and Prevention. Hospitalization Rates and characteritics of patients Hospitalized with laboratory-confirmed coronavirus disease 2019-COVID-NET, 14 states, March 1-30. MMWR (MorbMortalWklyRep). https://www.cdc.gov/mmwr/volumes/69/wr/mm6915e3.htm. Accessed September 7, 2020.
14. Ahrenfeldt LJ, Otavova M, Christensen K, Lindahl S. Sex and age differences in COVID-19 mortality in Europe. Res Sq. 2020. rs.3.rs-61444.
15. Federal Office of Public Health - Switzerland. Epidemiological Situation of COVID-19 in Switzerland and the Principality of Liechtenstein. https://www.bag.admin.ch/bag/en/home/krankheiten/ausbrueche-epidemien/ausbrueche-epidemien/novel-cov/situation-schweiz-und-international.html#.1680104524. Accessed September 10, 2020.
16. Robert Koch Institute. Coronavirus Disease 2019 (COVID-19) - Daily Situation Report of the Robert Koch Institute. https://www.rki.de/EN/Content/infections/epidemiology/outbreaks/COVID-19-Situationsberichte_Tab.html. Accessed September 10, 2020.
17. Chen WK, Peng BB, Liu XD, Wu ZG. Uncertainty based on Virus reports: what IS the effect OF SARS-CoV-2 ON male reproduc- tion? (COVID-19 and male reproduction). J Mens Health. 2020. 16(4):84-96.
18. Chung MK, Karnik S, Saef J, et al. SARS-CoV-2 and ACE2: the biology and clinical data setting the ARB and ACEI controversy. EBioMedicine. 2020;58:102907.
19. Jia HP, Look DC, Shi L, et al. ACE2 receptor expression and severe acute respiratory syndrome coronavirus infection depend on differentiation of human airway epithelia. J Virol. 2005;79(23): 14614-14621.
20. Sungnak W, Huang N, Becavin C, et al. SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes. Nat Med. 2020;26(5):681-687.
21. Hamming I, Timens W, Bulthuis ML, Lely AT, Navis G, van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogen- esis. J Pathol. 2004;204(2):621-637.
22. Zou X, Chen K, Zou J, Han P, Hao J, Han Z. Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the poten- tial risk of different human organs vulnerable to 2019-nCoV infection. Front Med. 2020;14(2):185-192.
23. Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020; 579(7798):270-273.
24. Bunyavanich S, Do A, Vicencio A. Nasal gene expression of angiotensin-converting enzyme 2 in children and adults. JAMA. 2020;323(23):2427-2429.

25. Tukiainen T, Villani AC, Yen A, et al. Landscape of X chromosome inactivation across human tissues. Nature. 2017;550(7675):244-248.

26. Bhatia K, Zimmerman MA, Sullivan JC. Sex differences in angiotensin-converting enzyme modulation of Ang (1-7) levels in normotensive WKY rats. Am J Hypertens. 2013;26(5):591-598.

27. Xie Y, Chen J, Wang X, Zhang F, Liu Y. Age- and gender-related difference of ACE2 expression in rat lung. Life Sci. 2006;78(19):2166-2171.

28. Stelzig KE, Canepa-Escaro F, Schillero M, Berdnikovs S, Prakash YS, Chiarella SE. Estrogen regulates the expression of SARS-CoV-2 receptor ACE2 in differentiated airway epithelial cells. Am J Physiol Lung Cell Mol Physiol. 2020;318(6):L1280-L1281.

29. Liu J, Ji H, Zheng W, et al. Sex differences in renal angiotensin converting enzyme 2 (ACE2) activity are 17beta-estradiol-dependent and sex chromosome-independent. Biol Sex Differ. 2010;1(1):6.

30. Zhang H, Rostami MR, Leopold PL, et al. Expression of the SARS-CoV-2 ACE2 Receptor in the Human airway epithelium. Am J Respir Crit Care Med. 2020;202(2):219-229.

31. Asselta R, Paraboschi EM, Mantovani A, Duga S. ACE2 and TMPRSS2 variants and expression as candidates to sex and country differences in COVID-19 severity in Italy. Aging (Albany NY). 2020;12(11):10087-10098.

32. Baughn LB, Sharma N, Elhaik E, Sekulic A, Bryce AH, Fonseca R. Targeting TMPRSS2 in SARS-CoV-2 infection. Mayo Clin Proc. 2020;95(9):1989-1999.

33. Vedenskii AN, Stoiko Iu M, Chalisov IA, Tulupov AN, Matveev SA. Pathogenesis of thrombus formation in varicose veins. Vestn Khir Im I Grek. 1988;141(9):41-43.

34. Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181(2):271-280.e8.

35. Heurich A, Hofmann-Winkler H, Gierer S, Liepold T, Jahn O, Pinheiro I. The X chromosome in immune functions: when a chromosome makes the difference. Nat Rev Immunol. 2010;10(8):594-604.

36. Wu H, Luo J, Yu H, et al. Cellular resolution maps of X chromosome inactivation: implications for neural development, function, and disease. Neuron. 2014;81(1):103-119.

37. Lyon MF. Gene action in the X-chromosome of the mouse (Mus musculus L.). Nature. 1961;190:372-373.

38. Wang J, Syrett CM, Kramer MC, Basu A, Atchison ML, Anguera MC. Unusual maintenance of X chromosome inactivation predisposes female lymphocytes for increased expression from the inactive X. Proc Natl Acad Sci U S A. 2016;113(14):E2029-E2038.

39. Cook IF. Sexual dimorphism of humoral immunity with human vaccines. Vaccine. 2008;26(29-30):3551-3555.

40. Klein SL. Age and gender differences in COVID-19-19. Lancet Infect Dis. 2010;10(5):338-349.

41. Burguete-Garcia AL, Conde-Gonzalez CJ, Jimenez-Mendez R, et al. Hepatitis C seroprevalence and correlation between viral load and viral genotype among primary care clients in Mexico. Salud Publica Mex. 2011;53(Suppl 1):S7-S12.

42. Murphy G, Pfeiffer R, Camargo MC, Rakbin CS. Meta-analysis shows that prevalence of Epstein-Barr virus-positive gastric cancer differs based on sex and anatomic location. Gastroenterology. 2009;137(3):824-833.

43. Puchhammer-Stockl E, Aberle SW, Heinzel. Association of age and gender with alphaherpesvirus infections of the central nervous system in the immunocompetent host. J Clin Virol. 2012;53(4):356-359.
adjusting for the level of viral replication. J Infect Dis. 2013;208(5):830-838.

64. Hadjadj J, Yatim N, Barnabei L, et al. Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients. Science. 2020;369(6504):718-724.

65. Pairo-Castineira E, Clohisey S, Klaric L, et al. Genetic mechanisms of critical illness in Covid-19. Nature. 2020. https://doi.org/10.1038/s41586-020-03065-y.

66. Liu D, Liu J, Zeng S, et al. Immunity-modulated sex disparity on COVID-19 prognosis. Clin Transl Med. 2020;10(5):e164.

67. Stoica GH, Samborschi C, Michiu V. Influence of sex and age on serum immunoglobulin concentrations in healthy subjects. Med Interne. 1978;16(1):23-31.

68. Farzadegan H, Hoover DR, Astemborski J, et al. Sex differences in HIV-1 viral load and progression to AIDS. Lancet. 1998;352(9139):1510-1514.

69. Jean CM, Honarmand S, Louie JK, Glaser CA. Risk factors for West Nile virus neuroinvasive disease, California. Emerg Infect Dis. 2005;13(12):1918-1920.

70. Engler RJ, Nelson MR, Klotz MM, et al. Half- vs full-dose trivalent inactivated influenza vaccine (2004-2005): age, dose, and sex effects on immune responses. Arch Intern Med. 2008;168(22):2405-2414.

71. He Z, Zhao C, Dong Q, et al. Effects of severe acute respiratory syndrome (SARS) coronavirus infection on peripheral blood lymphocytes and their subsets. Int J Infect Dis. 2005;9(6):323-330.

72. Fan H, Dong G, Zhao G, et al. Immunity-modulated sex disparity on COVID-19 prognosis. Clin Transl Med. 2020;10(5):e164.

73. Giamarellos-Bourboulis EJ, Netea MG, Rovina N, et al. Complex immune dysregulation in COVID-19 patients with severe Respiratory failure. Cell Host Microbe. 2020;27(6):992-1000.e3.

74. Hajek M, Sibl O, Stedry V. [Stenosis of the cervical esophagus in the mucosal form of epidermolysis bullosa]. Rozhl Chir. 1988;67(12):790-792.

75. Takahashi T, Ellingson MK, Wong P, et al. Sex differences in immune responses that underlie COVID-19 disease outcomes. Nature. 2020.

76. Wong CK, Lam CW, Wu AK, et al. Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome. Clin Exp Immunol. 2004;136(1):95-103.

77. Mahalawai WH, Khabour OF, Zhang Q, Mahkdoum HM, Suliman BA. MERS-CoV infection in humans is associated with a pro-inflammatory Th1 and Th17 cytokine profile. Cytokine. 2018;104:8-13.

78. Klein SL, Flanagan KL. Sex differences in immune responses. Nat Rev Immunol. 2016;16(10):626-638.

79. Zeng F, Dai C, Cai P, et al. A comparison study of SARS-CoV-2 IgG antibody between male and female COVID-19 patients: a possible reason underlying different outcome between sex. J Med Virol. 2020;92(10):2050-2054.

80. Fan H, Dong G, Zhao G, et al. Gender differences of B cell signature in healthy subjects underlie disparities in incidence and course of SLE related to estrogen. J Immunol Res. 2014;2014:814598.

81. Breit Haupt-Faloppa AC, Correia CJ, Prado CM, Stilanso RS, Ure-shino RP, Moreira LFP. 17beta-Estradiol, a potential ally to alleviate SARS-CoV-2 infection. Clin [Sao Paulo]. 2020,75:e1980.

82. Capuano A, Rossi F, Paolillo G. Covid-19 kills more men than women: an Overview of possible Reasons. Front Cardiovasc Med. 2020;7:131.

83. Straub RH. The complex role of estrogen in inflammation. Endocr Rev. 2007;28(5):521-574.

84. Channappanavar R, Fett C, Mack M, Ten Eyck PP, Meyerholz DK, Perlman S. Sex-based differences in susceptibility to severe acute Respiratory syndrome coronavirus infection. J Immunol. 2017;198(10):4046-4053.

85. Costeira R, Lee KA, Murray B, et al. Estrogen and COVID-19 symptoms: associations in women from the COVID Symptom Study. medRxiv. 2020.2020. https://doi.org/10.1101/2020.07.30.20164921.

86. Ding T, Zhang J, Wang T, et al. A multi-hospital study in Wuhan, China:protective effects of non-menopause and female Hormones on SARS-CoV-2 infection. medRxiv. 2020. https://doi.org/10.1101/2020.03.26.20043943.

87. Rowland SP, O’Brien Bergin E. Screening for low testosterone and age on needed for early identification and treatment of men at high risk of mortality from Covid-19. Crit Care. 2020;24(1):367.

88. Rastrelli G, Di Stasi V, Inglese F, et al. Low testosterone levels predict clinical adverse outcomes in SARS-CoV-2 pneumonia patients. Andrology. 2020;9(1):88-98.

89. Foo YZ, Nakagawa S, Rhodes G, Simmons LW. The effects of sex hormones on immune function: a meta-analysis. Biol Rev Camb Philos Soc. 2017;92(1):551-571.

90. Trailsh A, Bolanos J, Nair S, Saad F, Morganter A. Do androgens modulate the Pathophysiological Pathways of inflammation? Appraising the contemporary evidence. J Clin Med. 2018;7(12):549.

91. Mehta P, McCuley BF, Brown M, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395(10229):1033-1034.

92. Furman D, Heijblum BP, Simon N, et al. Systems analysis of sex differences reveals an immunosuppressive role for testosterone in the response to influenza vaccination. Proc Natl Acad Sci U S A. 2014;111(2):869-874.

93. Giagulli VA, Guastamacchia E, Magrone T, et al. Worse progression of COVID-19 in men: is testosterone a key factor? Andrology. 2020;9(1):53-64.

94. Al-Lami RA, Urban RJ, Volpi E, Albargi AMA, Baillargeon J. Sex Hormones and novel corona virus infectious disease (COVID-19). Mayo Clin Proc. 2020;95(8):1710-1714.

95. Mijgo M, Basaria S, Bie A, et al. Correlation between testosterone and the inflammatory marker soluble interleukin-6 receptor in older men. J Clin Endocrinol Metab. 2006;91(1):345-347.

96. Posma E, Moes H, Heineman MJ, Faas MM. The effect of testosterone on cytokine production in the specific and non-specific immune response. Am J Reprod Immunol. 2004;52(4):237-243.

97. Ackermann M, Verleden SE, Kuehnel M, et al. Pulmonary vascular endothelitis, thrombosis, and angiogenesis in covid-19. N Engl J Med. 2020;383(2):120-128.

98. Goshua G, Pine AB, Meizlish ML, et al. Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre, cross-sectional study. Lancet Haematol. 2020;7(8):e575-e582.

99. Ladiku E, Sivaloganathan H, Milne KM, et al. Von Willebrand factor (vWF): marker of endothelial damage and thrombotic risk in older men. J Clin Endocrinol Metab. 2018;7 (12):549.

100. Trumble BC, Blackwell AD, Stieglitz J, et al. Associations between male testosterone and immune function in a pathogenically stressed forager-horticultural population. Am J Phys Anthropol. 2016;161(3):494-505.

101. Cayan S, Uguz M, Saylam B, Akbay E. Effect of serum total testosterone and its relationship with other laboratory parameters on the prognosis of coronavirus disease 2019 (COVID-19) in SARS-CoV-2 infected male patients: a cohort study. Aging Male. 2020;23:1-11.

102. Hackett G, Kirby M. COVID-19, type 2 diabetes, and Hypogonadism: Lessons for acute management and long-term Prevention. Androg Clin Res Ther. 2020;1(1):22-31.

103. Park M, Kim S, Won Y. Relationship between testosterone deficiency and the cardiovascular Risk factors, diabetes and Hypertension. J Mens Health. 2020;16(4):97-109.
104. Jain V, Yuan J-M. Systematic review and meta-analysis of predictive symptoms and comorbidities for severe COVID-19 infection. medRxiv. 2020. https://doi.org/10.1101/2020.03.15.20035360.

105. GBD Disease Injury I, Prevalence C. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392(10159):1789-1858.

106. Zhao Q, Meng M, Kumar R, et al. The impact of COPD and smoking history on the severity of COVID-19: a systemic review and meta-analysis. J Med Virol. 2020;92(1):1915-1921.

107. Zheng Z, Peng F, Xu B, et al. Risk factors of critical & mortal COVID-19 cases: a systematic literature review and meta-analysis. J Infect. 2020;81(2):e16-e25.

108. Guo FR. Active smoking is associated with severity of coronavirus disease 2019 (COVID-19): an update of a meta-analysis. Tob Induc Dis. 2020;18:37.

109. Cai H. Sex difference and smoking predisposition in patients with COVID-19. Lancet Respir Med. 2020;8(4):e20.

110. WHOER Team, Agua-Agum J, Ariyarajah A, et al. Ebola virus disease among male and female Persons in west africa. N Engl J Med. 2016;374(1):96-98.

111. Johnson HD, Sholcosky D, Gabello K, Ragni R, Ogonosky N. Sex differences in public restroom handwashing behavior associated with visual behavior prompts. Percept Mot Ski. 2003;97(3 Pt 1): 805-810.

112. Baig AM. Chronic COVID syndrome: need for an appropriate medical terminology for long-COVID and COVID long-Haulers. J Med Virol. 2020.

113. Carfì A, Bernabei R, Landi F, Group fGAC-P-ACS. Persistent symptoms in patients after acute COVID-19. JAMA. 2020;324(6): 603-605.

114. Townsend L, Dyer AH, Jones K, et al. Persistent fatigue following SARS-CoV-2 infection is common and independent of severity of initial infection. medRxiv. 2020. https://doi.org/10.1101/2020.07.29.20164293.

115. Sudre CH, Murray B, Varsavsky T, et al. Attributes and predictors of Long-COVID: analysis of COVID cases and their symptoms collected by the Covid Symptoms Study App. Medrxiv. 2020. https://doi.org/10.1101/2020.10.19.20214494.

116. Leynaert B, Sunyer J, Garcia-Esteban R, et al. Gender differences in prevalence, diagnosis and incidence of allergic and non-allergic asthma: a population-based cohort. Thorax. 2012;67(7): 625-631.

How to cite this article: Alwani M, Yassin A, Al-Zoubi RM, et al. Sex-based differences in severity and mortality in COVID-19. Rev Med Virol. 2021;1–11. https://doi.org/10.1002/rmv.2223